Table 1.
Summary of published continuous and split course TMT series
| Study Design | Split/ | Follow-up | N | Chemotherapy | RT Dose | Neoadjuvant/ | Complete | Salvage | CSS | OS | |
| Continuous | (months) | Regimen | Adjuvant | Response | RC Rate | ||||||
| Course | Regimen | Rate | |||||||||
| James et al., 2012 [14] | Prospective, Phase III | Continuous | 69.9 | 182 | 5-FU and Mitomycin C×2 | 55 or 64 Gy | – | – | 11.4% | – | 48% (5 yr) |
| Tunio et al., 2012 [15] | Prospective Phase III | Continuous | 60.0 | 200 | Cisplatin [Weekly] | 65 Gy | – | 93% | – | – | 52% (5 yr) |
| Zapatero et al., 2012 [31] | Retrospective | Split | 60.0 | 39 | Cisplatin (Paclitaxel: n = 5) | 64.8 Gy | – | 80% | 33% | 82% (5 yr) | 73% (5 yr) |
| Efstathiou et al., 2012 [19] | Retrospective | Split | 92.4 | 348 | Various | Various | Various Neoadjuvant and Adjuvant Regimens | 78% | 29% | 5 yr – 64% | 5 yr – 52% |
| 10 yr – 59% | 10 yr – 35% | ||||||||||
| 15 yr – 57% | 15 yr – 22% | ||||||||||
| Lagrange et al., 2011 [73] | Prospective Phase II | Split | 96.0 | 51 | Cisplatin and 5-FU×3 | 63 Gy | – | – | 33.3% | – | 8 yr – 36% |
| Choudhury et al., 2011 [72] | Prospective Phase II | Continuous | 36.0 | 50 | Gemcitabine [Weekly] | 52.5 Gy | – | 82% | 14% | 3 yr – 82% | 3 yr – 75% |
| 5 yr – 78% | 5 yr – 65% | ||||||||||
| Krause et al., 2011 [30] | Retrospective | Split | 71.5 | 473 | Various | Various (RT only: n = 126) | – | 70.4% | – | – | 5 yr – 49% |
| 10 yr – 30% | |||||||||||
| Sabaa et al., 2010 [22] | Retrospective | Split | 47.0 | 104 | Cisplatin×2 | 60–65 Gy | Neoadjuvant Gemcitabine and Cisplatin×3 | 78.8% | 16.7% | 5 yr – 76% | 5 yr – 68% |
| Aboziada et al., 2009 [74] | Retrospective | Split | 18.0 | 50 | Cisplatin [Weekly] | 66 Gy | – | 60% | 28% | 1.5 yr – 84% | 1.5 yr – 100% |
| Kaufman et al., 2009 [69] | Prospective Phase I + II | Split | 49.4 | 80 | Cisplatin [Weekly] + Paclitaxel×5 | 64.3 Gy | AdjuvantCisplatin and Gemcitabine×4 | 81% | 12.5% | 5 yr – 71% | 5 yr – 56% |
| Perdona et al., 2008 [21] | Retrospective | Continuous | 66.0 | 78 | Cisplatin (Carboplatin: n = 25) | 65 Gy | Neoadjuvant CMV×2 | 85.7% | 20.2% | 5 yr – 79% | 5 yr – 72% |
| Weiss et al., 2007 [65] | Retrospective | Continuous | 27.0 | 112 | Cisplatin and 5-FU×2 | 55.8–59.4 Gy | – | 88% | 17% | 5 yr – 82% | 5 yr – 74% |
| Gogna et al., 2006 [70] | Prospective Phase II | Continuous | 23.0 | 113 | Cisplatin [Weekly] | 63–64 Gy | – | 70% | 15% | 5 yr – 50% | |
| Cobo et al., 2006 [27] | Retrospective | Split | 69.4 | 29 | Cisplatin×2 | 64.8 Gy | Neoadjuvant CMV×2 or Gemcitabine and Cisplatin | 86% | 24.1% | – | 6 yr – 72% |
| Kragelj et al., 2005 [61] | Prospective Phase II | Continuous | 123.6 | 84 | Vinblastine [Weekly] | 63.8–64 Gy | – | 78% | 8.3% | 9 yr – 51% | 9 yr – 25% |
| Peyromaure et al., 2004 [32] | Retrospective | Split | 36.3 | 43 | Cisplatin and 5-FU×2 | 24 Gy | – | 74.4% | 25.6% | 3 yr – 75% | – |
| 5 yr – 60% | |||||||||||
| Hussain et al., 2004 [77] | Prospective Phase I + II | Continuous | 50.7 | 41 | Mitomycin C and 5 FU×2 | 55 Gy | – | 71% | 19.5% | 2 yr – 68% | 2 yr – 49% |
| 5 yr – 36% | |||||||||||
| Danesi et al., 2004 [20] | Retrospective | Continuous | 82.2 | 77 | Cisplatin and 5-FU | 69 Gy | Neoadjuvant CMV×2 | 80.5% | 22.1% | 5 yr – 75% | 5 yr – 59% |
| 10 yr – 73% | 10 yr – 55% | ||||||||||
| Hagan et al., 2003 [67] | Prospective Phase I + II | Split | 26.0 | 47 | Cisplatin [Weekly] | 64.8 Gy | Adjuvant CMV×3 | 74% | 25.5% | – | 3 yr – 61% |
| Rödel et al., 2002 [28] | Retrospective | Continuous | 60.0 | 415 | Various | 45 – 69.4 Gy (RT alone: n = 126) | – | 72% | 20% | 5 yr – 56% | 5 yr – 51% |
| 10 yr – 42% | 10 yr – 31% | ||||||||||
| Kaufman et al., 2000 [78] | Prospective Phase I + II | Split | 29.0 | 34 | Cisplatin and 5-FU×4 | 44 Gy | – | 67% | 29.4% | 3 yr – 83% | – |
| Arias et al., 2000 [23] | Retrospective | Split | 73.0 | 50 | Cisplatin×1 | 65 Gy | Neoadjuvant M-VAC×2 | 68% | 26% | – | 5 yr – 48% |
| Shipley et al., 1998 [16] | Prospective Phase III (Arm 1: No Neoadjuvant Therapy) | Split | 60.0 | 62 | Cisplatin×3 | 64.8 Gy | – | 60% | 25.8% | – | 5 yr – 49% |
| Shipley et al., 1998 [16] | Prospective Phase III (Arm 2: With Neoadjuvant Therapy) | Split | 60.0 | 61 | Cisplatin×3 | 64.8 | Neoadjuvant CMV×2 | 72.5% | 17% | – | 5 yr – 48% |
| Kachnic et al., 1997 [24] | Retrospective | Split | 52.8 | 106 | Cisplatin×3 | 64.8 Gy | Neoadjuvant CMV×2 | 80% | 21.7% | 5 yr – 60% | 5 yr – 52% |
| Fellin et al., 1997 [26] | Prospective Phase II | Split | 46.0 | 56 | Cisplatin | 64 Gy | Neoadjuvant CMV×2 | 50% | 46.4% | 5 yr – 59% | 5 yr – 54% |
| Tester et al., 1996 [25] | Prospective Phase II | Split | 52.8 | 91 | Cisplatin×3 | 64.8 Gy | Neoadjuvant CMV×2 | 75% | 39.5% | – | 4 yr – 62% |
| Housset et al., 1993 [17] | Prospective Phase III | Split | 27.0 | 54 | Cisplatin and 5-FU×4 | 44 Gy | – | 74% | – | 3 yr – 62% | 3 yr – 59% |
| Tester et al., 1993 [75] | Prospective Phase III | Split | 36.0 | 48 | Cisplatin×3 | 64 Gy | – | 66% | 20.8% | – | 3 yr – 64% |
| Russell et al., 1990 [76] | Prospective Phase II | Split | 18.0 | 34 | 5-FU | 60 Gy | – | 81% | 29.4% | – | 4 yr – 64% |
RT = Radiation Therapy; RC = Radical Cystectomy; CSS = Cancer Specific Survival; OS = Overall Survival; 5-FU = 5-Fluorouracil; CMV = Cisplatin, Vinblastine, Methotrexate; M-VAC = Methotrexate, Cisplatin, Adriamycin, Vinblastine; yr = Year.